Skip to content

Study · Observational study · 2021

9 results

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.

Huang WC, Chen YC, Wu CH, Ko Y

Scientific reports14 Jan 2021Cited by 8 (Europe PMC)

PMID33446845 (opens in a new tab)PMCIDPMC7809152 (opens in a new tab)DOI10.1038/s41598-020-80753-9 (opens in a new tab)PepBankPUB-33446845
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovascular diseases (CVD) risk. This is a retrospective cohort study using Taiwan's Health and Welfare Database. A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin. The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01). Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001). In conclusion, compared to basal insulin, liraglutide was found to be associated with reduced risk of a composite CVD outcome, nonfatal stroke, and all-cause mortality among high CVD risk patients with T2DM. In addition, liraglutide users had lower inpatient, ER, and total medical costs, but they had higher outpatient and total pharmacy costs.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, the liraglutide group had a lower risk of a composite cardiovascular outcome than the basal insulin group.

    In plain wordsIn adults with type 2 diabetes at high heart risk, liraglutide was linked to fewer combined heart events than basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseComposite cardiovascular outcome
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.65 HR
    composite CVD outcome

    Source sentences

    Summary
    The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, the liraglutide group had a lower risk of all-cause mortality than the basal insulin group.

    In plain wordsIn adults with type 2 diabetes at high heart risk, liraglutide was linked to fewer deaths from any cause than basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.4 HR
    all-cause mortality

    Source sentences

    Summary
    The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, the liraglutide group had a lower risk of nonfatal stroke than the basal insulin group.

    In plain wordsIn adults with type 2 diabetes at high heart risk, liraglutide was linked to fewer nonfatal strokes than basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseNonfatal stroke
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.54 HR
    nonfatal stroke

    Source sentences

    Summary
    The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  4. 04HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had lower median per-patient-per-month inpatient costs.

    In plain wordsHospital stay costs were lower with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseInpatient costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  5. 05HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had lower median per-patient-per-month emergency room costs.

    In plain wordsEmergency room costs were lower with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseEmergency room costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  6. 06HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had lower median per-patient-per-month total medical costs.

    In plain wordsTotal medical costs were lower with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal medical costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  7. 07HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had higher median per-patient-per-month outpatient costs.

    In plain wordsOutpatient visit costs were higher with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseOutpatient costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  8. 08HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had higher median per-patient-per-month total pharmacy costs.

    In plain wordsMedicine costs were higher with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal pharmacy costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.
  9. 09HumanObservational studyOther

    Compared with basal insulin, the liraglutide group had higher median per-patient-per-month total costs.

    In plain wordsOverall costs were higher with liraglutide than with basal insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal costs
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001).
    2 context sentences
    Summary · context
    This is a retrospective cohort study using Taiwan's Health and Welfare Database.
    Summary · context
    A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.